Saturday 17 October 2026
Export VTRS’s income statement to Excel — free account
Viatris Inc.
VTRS Healthcare Drug Manufacturers Specialty & Generic
Viatris Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.3 billion, down 2.98% from fiscal 2024. In the quarter to June 2026, revenue grew 4.88%, EPS fell 2,464.1%, free cash flow grew 101.1% and total debt fell 18.1%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for five consecutive years.
18.66
0.44
+2.41%
Follow VTRS
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(21.09%) | (21.08%) | (1.96%) | (2.75%) | |
Piotroski F-Score |
4 | 5 | 6 | 7 | |
| (8.93%) | (8.93%) | (0.79%) | (1.12%) | ||
ROIC |
(5.43%) | (5.99%) | 0.32% | (0.20%) | |
Return on Tangible Assets |
(70.80%) | (66.21%) | (4.47%) | (6.68%) | |
Average Days of Receivables |
87.13 | 77.37 | 77.11 | 77.43 | |
Free Cash Flow per Share |
1.41 | 1.66 | 1.49 | 1.63 | |
Free Cash Flow |
1,637.60 | 1,939.00 | 1,721.60 | 1,890.60 | |
Capital Expenditures |
(345.20) | (376.90) | (447.10) | (440.20) | |
| Other line items | |||||
Cash ROIC |
5.05% | 6.37% | 5.59% | 6.63% | |
Accounts Receivable Turnover |
3.98 | 4.57 | 4.70 | 4.62 | |
Accounts Payable Turnover |
4.86 | 5.15 | 5.11 | 5.47 | |
Inventory Turnover |
2.21 | 2.37 | 2.38 | 2.34 | |
Average Days of Payables |
72.38 | 68.94 | 66.84 | 65.61 | |
Days of Inventory on Hand |
165.93 | 157.19 | 150.04 | 149.48 | |
Tax Rate |
(0.04) | (0.04) | (0.64) | (0.38) | |
Research and Development Expense of Revenue |
6.36% | 6.75% | 6.82% | 6.93% | |
Selling, General and Administrative Expense of Revenue |
26.98% | 26.53% | 25.92% | 27.01% | |
Share Based Compensation of Revenue |
1.14% | 1.24% | 1.17% | 1.17% | |
Interest Coverage |
(5.62) | (5.65) | 0.29 | (0.18) | |
Operating CF/Net income |
(0.54) | (0.66) | (7.31) | (5.68) | |
Depreciation/Fixed assets |
2.18 | 2.19 | 1.11 | 1.15 | |
Capex/Depreciation |
(0.06) | (0.07) | (0.16) | (0.16) | |
Revenue per Share |
12.13 | 12.21 | 12.60 | 12.67 | |
Operating CF per Share |
1.70 | 1.98 | 1.88 | 2.00 | |
Capex per Share |
(0.30) | (0.32) | (0.39) | (0.38) | |
Capex to Sales |
0.02 | 0.03 | 0.03 | 0.03 |
Columns are period end dates